{"id":"NCT02198794","sponsor":"Auspex Pharmaceuticals, Inc.","briefTitle":"Reducing Involuntary Movements in Participants With Tardive Dyskinesia","officialTitle":"An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-20","primaryCompletion":"2019-12-06","completion":"2020-12-14","firstPosted":"2014-07-24","resultsPosted":"2021-03-01","lastUpdate":"2022-04-01"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tardive Dyskinesia"],"interventions":[{"type":"DRUG","name":"SD-809","otherNames":["Deutetrabenazine; TEV-50717"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A: SD-809","type":"EXPERIMENTAL"},{"label":"Part B: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B: SD-809","type":"ACTIVE_COMPARATOR"},{"label":"Part C: SD-809","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.","primaryOutcome":{"measure":"Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal","timeFrame":"Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)","effectByArm":[{"arm":"SD-809","deltaMin":269,"sd":null},{"arm":"Part C: SD-809","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":82,"countries":["United States","Czechia","Germany","Hungary","Poland","Slovakia"]},"refs":{"pmids":["38557959","31296586"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":68,"n":337},"commonTop":["Anxiety","Depression","Somnolence","Weight decreased","Urinary tract infection"]}}